- Home
- LRE vs ASBP Comparison
LRE vs ASBP Comparison
Compare LRE & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRE
- ASBP
- Stock Information
- Founded
- LRE 2001
- ASBP 2021
- Country
- LRE Japan
- ASBP United States
- Employees
- LRE N/A
- ASBP N/A
- Industry
- LRE
- ASBP Biotechnology: Pharmaceutical Preparations
- Sector
- LRE
- ASBP Health Care
- Exchange
- LRE Nasdaq
- ASBP Nasdaq
- Market Cap
- LRE 17.6M
- ASBP 17.6M
- IPO Year
- LRE 2023
- ASBP N/A
- Fundamental
- Price
- LRE $1.20
- ASBP $0.24
- Analyst Decision
- LRE
- ASBP
- Analyst Count
- LRE 0
- ASBP 0
- Target Price
- LRE N/A
- ASBP N/A
- AVG Volume (30 Days)
- LRE 10.4K
- ASBP 363.3K
- Earning Date
- LRE 01-01-0001
- ASBP 05-24-2025
- Dividend Yield
- LRE N/A
- ASBP N/A
- EPS Growth
- LRE N/A
- ASBP N/A
- EPS
- LRE 0.29
- ASBP N/A
- Revenue
- LRE $117,804,154.00
- ASBP N/A
- Revenue This Year
- LRE N/A
- ASBP N/A
- Revenue Next Year
- LRE N/A
- ASBP N/A
- P/E Ratio
- LRE $4.10
- ASBP N/A
- Revenue Growth
- LRE 8.82
- ASBP N/A
- 52 Week Low
- LRE $1.10
- ASBP $0.32
- 52 Week High
- LRE $13.76
- ASBP $15.80
- Technical
- Relative Strength Index (RSI)
- LRE 46.94
- ASBP N/A
- Support Level
- LRE $1.22
- ASBP N/A
- Resistance Level
- LRE $1.29
- ASBP N/A
- Average True Range (ATR)
- LRE 0.12
- ASBP 0.00
- MACD
- LRE -0.01
- ASBP 0.00
- Stochastic Oscillator
- LRE 12.20
- ASBP 0.00
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.
About ASBP Aspire Biopharma Holdings Inc. Common Stock
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.